Dr.Manoj Pujari on LinkedIn: Labcorp is pleased to announce that we will be at (2024)

Persons under 50 are becoming more likely to be diagnosed with over a dozen different cancers as mentioned by global statistics. Although the rate of increase varies by nation and kind of cancer, projections based on worldwide statistics indicate that between 2019 and 2030, there will be a 30% increase in occurrences of early-onset cancer. Read more:

2

Stress can significantly impact our physical and mental health. Learn the three biggest sources of stress and discover how you can help reduce stress for your employees.

We recognize the link between human and environmental health and the leading role our company plays in creating a healthier world. We are proud to share our progress on initiatives that positively impact our employees, operations and the communities we serve.View our latest Corporate Responsibility Report.

1

Attending the ASGCT 27th Annual Meeting in Baltimore May 7-11? We’d love to help you advance your cell and gene therapy programs, and our dedicated scientists will be on-site at booth 1117 to discuss your specific needs. We look forward to seeing you there.#CellandGeneTherapy #ASGCT24

2

Labcorp is proud to support United Rheumatology/Specialty Networks during their Spring National Conference in San Antonio, Texas, on Friday, April 19, where we will be connecting during their Rheumatology Roundtable and sharing our commitment to improve lives every day.Learn more about our broad capabilities in #AutoimmuneTesting in #Rheumatology.

The expansion of Labcorp’s oncology solutions portfolio reflects our commitment to innovative solutions in cancer research and patient care.Read the press release. #AACR24 #Oncology #PrecisionMedicine #Biopharma #ClinicalResearch

1

Researchers have identified human gut bacteria that produce an enzyme that can change artery-clogging cholesterol into a less harmful version that the body is unable to absorb. The results suggest potential therapies for hypercholesterolemia. Read more:

Labcorp Oncology's scientific team recently published a manuscript in Oncology and Therapy that discusses the negative impact of single-gene testing (SGT) done prior to comprehensive genomic profiling (CGP) for patients with non-small cell lung cancer. SGT before CGP doubled subsequent CGP test cancelations due to tissue insufficiency and increased DNA extraction failures. Read the full manuscript: https://bit.ly/440dGR8#NSCLC #CGP #PrecisionOncology

3

Labcorp® Plasma Focus™ is a sensitive and specific multi-solid tumor NGS test focused on biomarkers for FDA-approved therapies. It enables personalized care based on each patient's unique tumor to help improve outcomes. Learn more.

1